Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L200 TCR-T
- Development stage
- Unknown
- Lead developer
- TCRCure Biotech
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
L200 TCR-T (also known as TC-L200S) is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by TCRCure Biotech. It is designed to target the Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) antigen, which is highly expressed in EBV-associated malignancies such as nasopharyngeal carcinoma and extranodal NK/T-cell lymphoma. To overcome the immunosuppressive tumor microenvironment of solid tumors, the TCR-T cells are engineered with a cytokine auto-secreting element that releases Interleukin-12 (IL-12), enhancing local immune activation, T-cell persistence, and anti-tumor efficacy. L200 TCR-T is currently in clinical development for the treatment of EBV-positive metastatic or refractory nasopharyngeal carcinoma and other EBV-associated cancers.
- Other names
- L200s TCR-TL-200s TCR-TL 200s TCR-TTC-L200sTC-L-200sTC-L 200s
02
Targets
CD3 (T-cell surface glycoprotein CD3)Epstein-Barr virus latent membrane protein 2-derived peptide–HLA class I complex (EBV LMP2–HLA-I complex)
Beyond the preview
Go deeper on L200 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L200 TCR-T.